Schiltigheim, France, April 25th, 2024 – ProteoGenix, a leading antibody development contract research organization (CRO), in a landmark collaboration with Cizzle Biotechnology Holdings PLC, an innovative UK-based diagnostics developer, announces the successful development of new antibodies targeting the CIZ1B biomarker, which is closely associated with early-stage lung cancer.
This innovation promises to transform early lung cancer detection...